Nanobody Humanization Service
Nanobody humanization is a critical step in the development of therapeutic VHH candidates. Although camelid-derived nanobodies exhibit many favorable drug-like properties, their non-human sequences may still introduce immunogenicity risks in clinical applications.
Successful humanization requires more than simple sequence replacement. Humanized nanobodies must retain binding affinity, specificity, stability, and developability while minimizing potential immune responses.
Our nanobody humanization workflows integrate sequence analysis, structural modeling, immunogenicity assessment, and rational engineering strategies to generate humanized VHH candidates with optimized therapeutic potential.
Key goals in Nanobody Humanization
Maintaining Affinity
Preserving Stability
Minimizing Immunogenicity
Maintaining Developability
Advantages of Our Nanobody Humanization Platform
Immunogenicity-focused optimization
Preservation of affinity and stability
Integrated developability assessment
Flexible downstream validation support
Our Humanization Strategy
Our workflows combine computational analysis with rational sequence engineering.
Structural Modeling and CDR Preservation
Homology modeling and structural analysis help preserve CDR conformations critical for target binding.
Rational Back-Mutation Design
Selective back-mutations are introduced when necessary to recover affinity or stability.
Immunogenicity Assessment
In silico analysis is performed to identify potential immunogenic sequence liabilities.
For more details please contact Custom Nanobody Discovery Platform
